<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amantadine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amantadine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Amantadine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10759" href="/d/html/10759.html" rel="external">see "Amantadine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13387" href="/d/html/13387.html" rel="external">see "Amantadine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50642731"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gocovri;</li>
<li>Osmolex ER</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865874"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ODAN-Amantadine;</li>
<li>PDP-Amantadine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F132715"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Parkinson Agent, Dopamine Agonist;</li>
<li>
                        Antiviral Agent;</li>
<li>
                        Antiviral Agent, Adamantane</li></ul></div>
<div class="block doa drugH1Div" id="F132679"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> The IR formulations are interchangeable with one another, but they are <b>not</b> interchangeable with the ER formulations; the ER formulations are <b>not</b> interchangeable with one another.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="96973e7e-5b87-46bc-933e-2327d4b89183">Drug-induced parkinsonism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Drug-induced parkinsonism (alternative agent): Note:</b> Use if patient cannot tolerate preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet: <b>Oral:</b> Initial: 129 mg once daily; may increase based on response and tolerability by increments of 129 to 193 mg in weekly intervals to a maximum dose of 322 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 100 mg twice daily; after 1 week, may increase based on response and tolerability to 300 mg/day in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5066','lexi-content-ref-Stroup.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5066','lexi-content-ref-Stroup.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ffaacd1e-62aa-433b-b373-ab0cf4b6b33b">Multiple sclerosis–related fatigue</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis–related fatigue (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients who fail nonpharmacologic interventions and remain symptomatic despite treatment of underlying conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Olek.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Olek.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> 100 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24321164','lexi-content-ref-22979982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24321164','lexi-content-ref-22979982'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8d334dad-2d86-49f3-b1ea-ca68e9496b35">Neuroleptic malignant syndrome, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroleptic malignant syndrome, moderate to severe (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in combination with supportive care, benzodiazepines, and dantrolene in patients with moderate to severe symptoms at presentation (eg, hyperthermia, evidence of rhabdomyolysis) and for those not responding to initial withdrawal of medication and supportive care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22732295','lexi-content-ref-27423483','lexi-content-ref-17541044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22732295','lexi-content-ref-27423483','lexi-content-ref-17541044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral or via NG tube:</b> Initial: 100 mg once daily; may titrate based on response and tolerability to a maximum of 400 mg/day in 2 or 3 divided doses. After the patient is stabilized and symptoms have resolved, consider taper over days to weeks rather than abrupt discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15062519','lexi-content-ref-22732295','lexi-content-ref-19299325','lexi-content-ref-30775657','lexi-content-ref-27423483','lexi-content-ref-17541044','lexi-content-ref-30858642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15062519','lexi-content-ref-22732295','lexi-content-ref-19299325','lexi-content-ref-30775657','lexi-content-ref-27423483','lexi-content-ref-17541044','lexi-content-ref-30858642'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7f5b6fc7-a60e-4659-bd84-ea7be843cd24">Parkinson disease, dyskinesias or mild motor symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease, dyskinesias (adjunctive therapy) or mild motor symptoms (monotherapy) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Extended release:</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule: <b>Oral:</b> Initial: 137 mg once daily; after 1 week, increase to usual dose of 274 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablet:<b> Oral:</b> Initial: 129 mg once daily; may be increased based on response and tolerability by increments of 129 to 193 mg in weekly intervals to a maximum dose of 322 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 100 mg twice daily or once daily (see: <b>Note</b>); after 1 week, may increase based on response and tolerability to usual maximum dose of 300 mg/day; some patients with dyskinesias may require up to 400 mg/day in 2 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Liang.1','lexi-content-ref-21217832','lexi-content-ref-Spindler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Liang.1','lexi-content-ref-21217832','lexi-content-ref-Spindler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In patients with a serious concomitant illness or those receiving high doses of other antiparkinson drugs, initiate at 100 mg once daily; may increase to 100 mg twice daily, if needed, after 1 to several weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b2d9655-3745-4090-b9e4-e090f9c7caad">Tardive dyskinesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tardive dyskinesia (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients who fail first-line treatments for tardive dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30791698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30791698'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 100 mg once daily; may increase over ≥4 days up to 400 mg/day, in 1 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10950469','lexi-content-ref-21121175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10950469','lexi-content-ref-21121175'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy: </b>Abrupt discontinuation may lead to worsening of Parkinson disease symptoms, hyperpyrexia, or changes in mental status. Reduce the dose by one-half for 1 to 2 weeks before discontinuing.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991617"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> For acute short-term use (ie, neuroleptic malignant syndrome) no specific dose adjustments can be provided (has not been studied). Dosing should be individualized, weighing risks and benefits of over- and underdosing, and titrated to effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7212501','lexi-content-ref-7035042','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7212501','lexi-content-ref-7035042','lexi-content-ref-Manu.1'])">Ref</a></span>):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Renally adjusted dose recommendations are based on a usual recommended dose of 100 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 50 mL/minute: 200 mg on day 1, then 100 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 15 to &lt;30 mL/minute: 200 mg on day 1, then 100 mg every other day.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute: 200 mg once every 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>):</i></p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Amantadine ER Dose Adjustments for Altered Kidney Function</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">eGFR<sup>a</sup></p></th>
<th align="left">
<p style="text-indent:0em;">ER tablet</p></th>
<th align="left">
<p style="text-indent:0em;">ER capsule</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> MDRD equation is recommended in the manufacturer’s labeling for determining eGFR.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">≥60 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">30 to &lt;60 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">Initial: 129 mg every other day; increase no more frequently than every 3 weeks to a maximum dose of 322 mg every other day.</p></td>
<td align="left">
<p style="text-indent:0em;">Initial: 68.5 mg once daily; after 1 week, increase to 137 mg once daily if needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">15 to &lt;30 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">Initial: 129 mg every 96 hours; increase no more frequently than every 4 weeks to a maximum dose of 322 mg every 96 hours.</p></td>
<td align="left">
<p style="text-indent:0em;">68.5 mg once daily.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;15 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">Use is contraindicated.</p></td>
<td align="left">
<p style="text-indent:0em;">Use is contraindicated.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (&lt;5% of the dose removed by a 4-hour hemodialysis session) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7212501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7212501'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i> Dose for CrCl &lt;15 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i> There are no specific dosage adjustment recommendations (has not been studied); however, since amantadine is unlikely to be dialyzed, dosing for CrCl &lt;15 mL/minute may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> Use is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i> There are no specific dosage adjustment recommendations (has not been studied); however, since amantadine is unlikely to be dialyzed, dosing for CrCl &lt;15 mL/minute may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> Use is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i> There are no specific dosage adjustment recommendations (has not been studied); however, since amantadine is unlikely to be dialyzed, dosing for CrCl &lt;15 mL/minute may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988860"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F132680"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing; some patients tolerate the IR formulations better when administered in 2 divided daily doses (to avoid adverse neurologic reactions).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy: </b>Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F132695"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13387" href="/d/html/13387.html" rel="external">see "Amantadine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ADHD):</b> Limited data available: Oral: Immediate release: Children ≥5 years and Adolescents: Initial: 50 mg/<b>day</b>; titrate up at 4 to 7 day intervals in 50 mg increments to effect; reported range: 50 to 150 mg/<b>day</b> in divided doses 1 to 3 times daily (morning, noon, and 4 PM); maximum daily dose (weight-dependent): &lt;30 kg: 100 mg/<b>day</b>; ≥30 kg: 150 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17979585','lexi-content-ref-21312290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17979585','lexi-content-ref-21312290'])">Ref</a></span>); dosing based on two small open-label trials (n=24, n=20; age range: 5 to 14 years) which suggested improvements in symptoms; the comparison trial with methylphenidate (n=40) showed both amantadine and methylphenidate yielded significant improvement in ADHD symptoms (50% reduction from baseline symptoms), with no significant differences in efficacy between the groups; more frequent side effects in the methylphenidate group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21312290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21312290'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1e5d33b8-e6b1-4783-a653-e78612649d5f">Autism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Autism (hyperactivity, irritability):</b> Very limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23390434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23390434'])">Ref</a></span>): Oral: Immediate release: Children ≥5 years and Adolescents: Initial: 2.5 mg/kg/dose once daily for 1 week, then increase to 2.5 mg/kg/dose twice daily; maximum daily dose: 200 mg/<b>day</b>; dosing based on short-term (4-week) double-blind, placebo-controlled trial of 39 pediatric patients (treatment group, n=19) which showed improvement in clinician-rated behavioral and hyperactivity ratings (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11392343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11392343'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4d92b00c-b10a-4a84-88fd-e77df64de219">Influenza A prophylaxis/treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza A prophylaxis/treatment: Note: </b>Amantadine should NOT be used for prophylaxis or treatment of influenza A infection due to high resistance rates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32900875','lexi-content-ref-CDC.2','lexi-content-ref-30566567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32900875','lexi-content-ref-CDC.2','lexi-content-ref-30566567'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;9 years: Immediate release: Oral: 4.4 to 8.8 mg/kg/<b>day </b>in 2 divided doses until symptom resolution for 24 to 48 hours; maximum daily dose: 150 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥9 years: Immediate release: Oral: 100 mg twice daily until symptom resolution for 24 to 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Immediate release: Oral: 200 mg once daily or 100 mg twice daily until symptom resolution for 24 to 48 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8832c8d5-2cfe-4c05-ae43-a3f855e015dd">Multiple sclerosis–associated lassitude</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis–associated lassitude (fatigue):</b> Limited data available; available dosing based on data in traumatic brain injury trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16170253','lexi-content-ref-17438239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16170253','lexi-content-ref-17438239'])">Ref</a></span>): Oral: Immediate release:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;10 years or ≥10 years and weighing &lt;40 kg: Oral: 2.5 mg/kg/dose twice daily; maximum daily dose: 150 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents weighing ≥40 kg: Oral: 100 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f970798-6260-4e76-a464-e73e2e2b6d2f">Traumatic brain injury</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Traumatic brain injury (TBI):</b> Limited data available: Oral: Immediate release:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents &lt;16 years: 4 to 6 mg/kg/<b>day</b> in 2 divided doses; maximum daily dose (age or weight dependent): If &lt;10 years or &lt;40 kg: 150 mg/<b>day</b>; if ≥10 years or ≥40 kg: 200 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16170253','lexi-content-ref-19404190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16170253','lexi-content-ref-19404190'])">Ref</a></span>). While total daily dose similar in trials, the reported dosing approaches and efficacy results are variable (eg, timing of therapy initiation, duration of study, outcome measures) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17729042']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17729042'])">Ref</a></span>). In an open-label, case-controlled trial of 27 pediatric patients with TBI within the last 24 months prior to enrollment (n=17 amantadine treatment, n=10 controls), patients received 5 mg/kg/<b>day</b> for entire study period of 12 weeks; results showed improvement in behavior (parental report) and a subset analysis suggested therapy more effective on cognition for those with more recent injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16170253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16170253'])">Ref</a></span>). In a double-blind, placebo-controlled crossover trial of seven pediatric patients (mean age: 12.7 years) with TBI within last 12 weeks prior to enrollment, therapy was initiated at 4 mg/kg/<b>day</b> up to 300 mg/<b>day</b> for 1 week, and increased to 6 mg/kg/<b>day</b> up to 400 mg/<b>day</b> for Weeks 2 and 3 of the study duration; improved consciousness observed during treatment period of study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19404190','lexi-content-ref-20129511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19404190','lexi-content-ref-20129511'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥16 years: Initial: 100 mg twice daily for 14 days; on Week 3 increase to 150 mg twice daily; may further increase to 200 mg twice daily on Week 4 if needed; dosing based on a multicenter, double-blind, placebo-controlled trial of 184 patients (age range: 16 to 65 years; treatment group, n=87) which showed 4 weeks of amantadine therapy initiated at 4 to 16 weeks postinjury increased the rate of functional recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22375973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22375973'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53575808"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment should be considered.</p></div>
<div class="block dohp drugH1Div" id="F53575809"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F57269829"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Impulse control and related disorders</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Epidemiologic studies have suggested an association between amantadine and <b>impulse control disorders</b> and related disorders, manifesting as <b>pathological gambling</b>, <b>increased libido </b>(hypersexuality), compulsive or binge buying/eating, and/or other intense urges in patients with Parkinson disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21391319','lexi-content-ref-31167116','lexi-content-ref-25745311','lexi-content-ref-21954056','lexi-content-ref-20457959','lexi-content-ref-21154480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21391319','lexi-content-ref-31167116','lexi-content-ref-25745311','lexi-content-ref-21954056','lexi-content-ref-20457959','lexi-content-ref-21154480'])">Ref</a></span>). However, some studies did not find an association (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31167116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31167116'])">Ref</a></span>). In addition, extremely limited data suggests amantadine may offer benefit for pathological gambling in patients with Parkinson disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23205015','lexi-content-ref-20687121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23205015','lexi-content-ref-20687121'])">Ref</a></span>). Overall, most studies evaluating impulse control disorders involve patients with Parkinson disease receiving direct dopamine agonists or multiple dopaminergic medications, therefore, further studies may be needed to fully elucidate amantadine’s role in impulse control disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21541715','lexi-content-ref-22784693','lexi-content-ref-21280095','lexi-content-ref-31733691','lexi-content-ref-30653247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21541715','lexi-content-ref-22784693','lexi-content-ref-21280095','lexi-content-ref-31733691','lexi-content-ref-30653247'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism of action of amantadine has not been fully elucidated, but it is thought to have both dopaminergic and antiglutaminergic properties (as a N-methyl-D-aspartate [NMDA] glutamate receptor antagonist). Dopaminergic effects are generally believed to increase the risk for impulse control disorders while antiglutaminergic effects are thought to reduce these compulsive behaviors. Therefore, amantadine’s dual properties suggest a complex role regarding impulse control disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24971012','lexi-content-ref-11392342','lexi-content-ref-30653247','lexi-content-ref-20687121','lexi-content-ref-21954056','lexi-content-ref-21154480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24971012','lexi-content-ref-11392342','lexi-content-ref-30653247','lexi-content-ref-20687121','lexi-content-ref-21954056','lexi-content-ref-21154480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Difficult to determine. For dopamine replacement therapies in general (not specific for amantadine), there may be a significant lag time between initiation of treatment and development of impulse control disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20457959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20457959'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors<b>: </b></i>
<b>Note:</b> Based primarily on data involving dopamine agonists:</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (for PD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34370054','lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34370054','lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34370054','lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34370054','lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of psychiatric symptoms (eg, anxiety, depression) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34370054','lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34370054','lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of impulse control disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31700703']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31700703'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Earlier onset of PD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34370054','lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34370054','lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of PD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34370054','lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34370054','lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31700703']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31700703'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking, current and past (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31700703','lexi-content-ref-31167116','lexi-content-ref-25745311','lexi-content-ref-23611687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31700703','lexi-content-ref-31167116','lexi-content-ref-25745311','lexi-content-ref-23611687'])">Ref</a></span>). <b>Note:</b> Conflicting evidence exists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34370054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34370054'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Livedo reticularis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amantadine frequently causes <b>livedo reticularis </b>(LR), a dermatologic condition of the small vessels causing reddish-blue reticulated patches primarily affecting the trunk and lower limbs, in adults with Parkinson disease. LR is typically asymptomatic and usually does not warrant discontinuation. If therapy is discontinued, LR is reversible and lesions typically resolve 2 to 4 weeks following cessation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30372725','lexi-content-ref-26560223','lexi-content-ref-22356509','lexi-content-ref-5467552','lexi-content-ref-31929122','lexi-content-ref-5580722','lexi-content-ref-22165049']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30372725','lexi-content-ref-26560223','lexi-content-ref-22356509','lexi-content-ref-5467552','lexi-content-ref-31929122','lexi-content-ref-5580722','lexi-content-ref-22165049'])">Ref</a></span>). LR has also been reported in children receiving off label uses of amantadine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21995348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21995348'])">Ref</a></span>). In addition, livedo racemosa has also been reported rarely with amantadine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26338517']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26338517'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Exact mechanism of amantadine is unknown, but it has been postulated that amantadine causes an interruption of the peripheral blood re-distribution, primarily in the dermal arteries or depletion of catecholamine stores in peripheral nerves (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5580722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5580722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Onset: Varied; it may occur within a few months to years after amantadine initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22356509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22356509'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (possible):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26560223','lexi-content-ref-5467552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26560223','lexi-content-ref-5467552'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amantadine may cause or exacerbate neuropsychiatric symptoms in adults, ranging from mood disturbances, hypersomnia or <b>insomnia</b>, nightmares, <b>confusion</b>
<b>, </b>memory disturbances, <b>disorientation</b>
<b>, and </b>
<b>agitation</b>
<b> to </b>
<b>severe delirium</b> and <b>psychotic symptoms</b> (eg, <b>paranoid ideation</b>, <b>delusion</b>, <b>visual or auditory</b>
<b>hallucination).</b> Psychotic symptoms have been attributed to underlying Parkinson disease, antiparkinsonian agents (including amantadine), or a combination of both. There are limited data suggesting antiparkinsonian drug therapy does not increase the risk of neuropsychiatric events, but rather arises in susceptible patients due to certain risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15480845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15480845'])">Ref</a></span>). Of note, neuropsychiatric events have also been reported in older adult patients receiving amantadine for influenza prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16942542','lexi-content-ref-10734005','lexi-content-ref-22674352','lexi-content-ref-28611642','lexi-content-ref-123540','lexi-content-ref-1771145','lexi-content-ref-2061537','lexi-content-ref-27103808','lexi-content-ref-9143857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16942542','lexi-content-ref-10734005','lexi-content-ref-22674352','lexi-content-ref-28611642','lexi-content-ref-123540','lexi-content-ref-1771145','lexi-content-ref-2061537','lexi-content-ref-27103808','lexi-content-ref-9143857'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>May be dose- and duration-related or due to underlying illness; the exact mechanism is unknown, although it has been postulated that psychotic events associated with amantadine may be due to enhanced dopamine effects and N-methyl-D-aspartate (NMDA) receptor antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27103808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27103808'])">Ref</a></span>). Other neurotransmitters may also play a role in neuropsychiatric effects, including cholinergic pathways, as amantadine also has anticholinergic properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15480845','lexi-content-ref-33614044','lexi-content-ref-9143857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15480845','lexi-content-ref-33614044','lexi-content-ref-9143857'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Confusion and hallucination: Peak incidence in some studies has been observed during the third and ninth month of amantadine therapy</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses or an abrupt change in dose (antiparkinsonian drugs in general) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28492457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28492457'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy (patients with Parkinson disease also receiving levodopa) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9143857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9143857'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid cognitive impairment or dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19515253','lexi-content-ref-9143857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19515253','lexi-content-ref-9143857'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (hallucinations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16942542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16942542'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant treatment with anticholinergic medications (hallucinations, confusion, and delirium) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-123540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-123540'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension and syncope</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amantadine may cause or exacerbate <b>orthostatic hypotension</b>. Orthostatic hypotension may be asymptomatic or symptomatic, leading to <b>dizziness</b> and <b>falling</b>. Of note, neurogenic orthostatic hypotension is a common feature in patients with Parkinson disease (PD) (regardless of medication use) and results in an impaired capacity to respond to postural changes due to autonomic dysfunction from neurodegenerative processes in the brain stem (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212','lexi-content-ref-28833562','lexi-content-ref-22336566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212','lexi-content-ref-28833562','lexi-content-ref-22336566'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unclear, although orthostatic hypotension has been attributed to amantadine’s dopaminergic effects. In addition, other properties of amantadine may also play a role, including its arrhythmogenic properties (negative inotropic and chronotropic activity) as well as potential dose-dependent effects on cardiac muscarinic receptors. Amantadine also affects NMDA receptors which may play a role in bradycardia from chemoreflex activation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22336566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22336566'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22336566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22336566'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Autonomic dysfunction (as with PD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications that may cause orthostatic hypotension (eg, antihypertensive or antiarrhythmic medications, diuretics, levodopa, monoamine oxidase inhibitors, tricyclic antidepressants) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212','lexi-content-ref-1771145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212','lexi-content-ref-1771145'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular disease (eg, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypovolemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger patients with asthenic features (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Abrupt withdrawal or rapid dosage reduction of amantadine has been associated with an acute and potentially fatal <b>withdrawal syndrome</b> resembling neuroleptic malignant syndrome (NMS). The syndrome has been referred to as acute akinesia, parkinsonism-hyperpyrexia syndrome (PHS), or neuroleptic malignant-like syndrome. The syndrome is very similar to NMS but occurs in a setting of withdrawal following exposure to dopamine agonists, levodopa, or amantadine in patients not receiving neuroleptics. In the setting of dopamine agonist therapy, it has also been referred to as dopamine agonist withdrawal syndrome. Regardless of terminology used, symptoms may begin with confusion or delirium and progress to unresponsiveness, catatonia, muscle rigidity, diaphoresis, tachycardia, pyrexia, autonomic instability, and elevated creatine kinase. Case reports describe symptoms usually resolving, typically within days, following the re-initiation of antiparkinson medication; however, in up to one-third of patients, there may be permanent sequelae or patients may not recover to previous baseline state (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34190209','lexi-content-ref-28492457','lexi-content-ref-30581218','lexi-content-ref-11421428','lexi-content-ref-34324057','lexi-content-ref-28611642','lexi-content-ref-18712508','lexi-content-ref-12735913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34190209','lexi-content-ref-28492457','lexi-content-ref-30581218','lexi-content-ref-11421428','lexi-content-ref-34324057','lexi-content-ref-28611642','lexi-content-ref-18712508','lexi-content-ref-12735913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Exact mechanism unknown; may be dose- and duration-related. Symptoms are likely to due to central dopaminergic depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34190209','lexi-content-ref-30581218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34190209','lexi-content-ref-30581218'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in several cases involving amantadine, onset of symptoms ranged from 1 to 3 days following abrupt withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34190209']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34190209'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt withdrawal or dosage decrease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33614044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33614044'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33614044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33614044'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33614044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33614044'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33614044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33614044'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F132642"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Orthostatic hypotension (13%; including orthostatic dizziness, syncope, presyncope, and hypotension)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension')">table 1</a>)</span><span class="table-link" style="display:none;">Orthostatic Hypotension</span>, peripheral edema (16%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic Hypotension" frame="border" id="lexi-content-orthostatic-hypotension" rules="all">
<caption style="text-align:center;">
<b>Amantadine: Adverse Reaction: Orthostatic Hypotension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">274 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Treatment of dyskinesia or “off” episodes in patients with Parkinson disease receiving concomitant levodopa-based therapy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (13%), xerostomia (16%; may be more common in females)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (16%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 2</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, falling (13%; may be more common in adults ≥65 years of age)<span class="lexi-table-link-container"> (<a aria-label="Falling table link" class="lexi-table-link" data-table-id="lexi-content-falling" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-falling')">table 3</a>)</span><span class="table-link" style="display:none;">Falling</span>, hallucination (21%; including auditory hallucination and visual hallucination; may be more common in adults ≥65 years of age)<span class="lexi-table-link-container"> (<a aria-label="Hallucination table link" class="lexi-table-link" data-table-id="lexi-content-hallucination" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hallucination')">table 4</a>)</span><span class="table-link" style="display:none;">Hallucination</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Amantadine: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">274 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Treatment of dyskinesia or “off” episodes in patients with Parkinson disease receiving concomitant levodopa-based therapy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Falling" frame="border" id="lexi-content-falling" rules="all">
<caption style="text-align:center;">
<b>Amantadine: Adverse Reaction: Falling</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">274 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Treatment of dyskinesia or “off” episodes in patients with Parkinson disease receiving concomitant levodopa-based therapy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hallucination" frame="border" id="lexi-content-hallucination" rules="all">
<caption style="text-align:center;">
<b>Amantadine: Adverse Reaction: Hallucination</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">274 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Treatment of dyskinesia or “off” episodes in patients with Parkinson disease receiving concomitant levodopa-based therapy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Livedo reticularis (6%; may be more common in females)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Livedo Reticularis" frame="border" id="lexi-content-livedo-reticularis" rules="all">
<caption style="text-align:center;">
<b>Amantadine: Adverse Reaction: Livedo Reticularis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">274 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Treatment of dyskinesia or “off” episodes in patients with Parkinson disease receiving concomitant levodopa-based therapy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dyschromia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (1% to 5%), decreased appetite (6%), diarrhea (1% to 5%), nausea (8%), vomiting (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Benign prostatic hypertrophy (6%), urinary tract infection (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (4%; may be more common in females), agitation (1% to 5%), anxiety (7%), apathy (2%), ataxia (3%; may be more common in males), confusion (3%)<span class="lexi-table-link-container"> (<a aria-label="Confusion table link" class="lexi-table-link" data-table-id="lexi-content-confusion" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-confusion')">table 5</a>)</span><span class="table-link" style="display:none;">Confusion</span>, delusion (&lt;3%), depression (6%; including depressed mood), drowsiness (&lt;3%), dystonia (3%), fatigue (&lt;3%), headache (6%), illusion (&lt;3%), insomnia (7%)<span class="lexi-table-link-container"> (<a aria-label="Insomnia table link" class="lexi-table-link" data-table-id="lexi-content-insomnia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-insomnia')">table 6</a>)</span><span class="table-link" style="display:none;">Insomnia</span>, irritability (1% to 5%), nervousness (1% to 5%), paranoid ideation (&lt;3%), suicidal ideation (≤2%), suicidal tendencies (≤2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Confusion" frame="border" id="lexi-content-confusion" rules="all">
<caption style="text-align:center;">
<b>Amantadine: Adverse Reaction: Confusion</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">274 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Treatment of dyskinesia or “off” episodes in patients with Parkinson disease receiving concomitant levodopa-based therapy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Insomnia" frame="border" id="lexi-content-insomnia" rules="all">
<caption style="text-align:center;">
<b>Amantadine: Adverse Reaction: Insomnia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amantadine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">274 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Treatment of dyskinesia or “off” episodes in patients with Parkinson disease receiving concomitant levodopa-based therapy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Joint swelling (3%), muscle spasm (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (4%), cataract (3%; may be more common in females), dry eye syndrome (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (3%), dry nose (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure, hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Eczema, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia, neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking, amnesia, asthenia, euphoria, psychosis, seizure, slurred speech</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal edema, decreased visual acuity, oculogyric crisis, optic nerve palsy, photophobia, visual disturbance (including punctate subepithelial or other corneal opacity)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (including malignant arrhythmias) (Kocaş 2015), hypotension, tachycardia (Kocaş 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase, increased lactate dehydrogenase</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysphagia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, leukocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, aggressive behavior (Stewart 1987), coma (Macchio 1993), EEG pattern changes (Estraneo 2015), hypertonia, impulse control disorder (including excessive eating, excessive shopping, increased libido, pathological gambling) (Walsh 2012), mania (Neagoe 2013), neuroleptic malignant syndrome (associated with dosage reduction or abrupt withdrawal of amantadine) (Ito 2001), paresthesia, sudden onset of sleep, tremor (Strong 1991), withdrawal syndrome (including delirium, exacerbation of Parkinson disease, or stupor) (Marxreiter 2017, Murray 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hypokinesia, increased creatine phosphokinase in blood specimen</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Keratitis (Nogaki 1993), mydriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory failure (Cattoni 2014), pulmonary edema (Cattoni 2014), tachypnea</p></div>
<div class="block coi drugH1Div" id="F132656"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to amantadine or any component of the formulation; end-stage renal disease (CrCl &lt;15 mL/minute/1.73 m<sup>2</sup>) (extended release only).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Renal impairment (CrCl &lt;15 mL/minute).</p></div>
<div class="block war drugH1Div" id="F132639"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving). Patients taking amantadine for Parkinson disease have reported falling asleep while engaged in activities of daily living, sometimes without warning. Patients with a concomitant sleep disorder may be at a greater risk. There is insufficient information that dose reduction will eliminate episodes of falling asleep or daytime somnolence.</p>
<p style="text-indent:-2em;margin-left:4em;">• Melanoma: Risk for melanoma development is increased in Parkinson disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation/depression: There have been reports of suicidal ideation/attempt and depression in patients with and without a history of psychiatric illness. May exacerbate mental problems in patients with a history of mental illness.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with heart failure, peripheral edema, or orthostatic hypotension. Dosage reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Eczema: Use with caution in patients with a history of recurrent and eczematoid dermatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Avoid in untreated angle closure glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; rarely, reversible elevations in transaminases have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychotic disorders: Use is not recommended in patients with preexisting psychotic disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended. Use of the extended-release products is contraindicated in end-stage renal disease (CrCl &lt;15 mL/minute/1.73 m<sup>2</sup>).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; may be more susceptible to CNS effects (using 2 divided daily doses of immediate-release products may minimize this effect). These patients may require dosage reductions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Tolerance has also been reported with long-term use (Zubenko 1984).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53575803"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F132650"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gocovri: 68.5 mg, 137 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (10 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet ER 24 Hour Therapy Pack, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Osmolex ER: 129 &amp; 193 MG (60 ea [DSC]) [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Osmolex ER: 129 mg [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Osmolex ER: 193 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Osmolex ER: 258 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p></div>
<div class="block geq drugH1Div" id="F132635"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F132659"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Gocovri Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">68.5 mg (per each): $66.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">137 mg (per each): $66.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Amantadine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.97 - $2.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Amantadine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $0.15 - $1.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Osmolex ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">129 mg (per each): $23.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">193 mg (per each): $23.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Amantadine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.73 - $2.74</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865875"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (500 mL)</p></div>
<div class="block adm drugH1Div" id="F50815269"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">ER capsule: Administer at bedtime with or without food. Swallow whole; do not crush, chew, or divide capsules. If needed, sprinkle entire contents on a small amount (teaspoonful) of soft food, such as applesauce, and administer immediately without chewing.</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet: Administer in the morning without regard to food. Swallow whole; do not crush, chew, or divide tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule, extended release: Capsule may be opened and contents sprinkled onto soft food of choice. Patient should be instructed to swallow the mixture without biting down or chewing.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablet, extended release: Do not cut, crush, or chew. Switch to IR formulation or consider amantadine ER capsule since it can be opened.</p></div>
<div class="block admp drugH1Div" id="F52612214"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Immediate release: May be taken without regard to food. For regimens with multiple daily dosing, timing of doses may vary based upon patient tolerance (eg, if insomnia develops, administer evening dose several hours before bedtime) and use (for ADHD, administer morning and noon; if thrice-daily dosing, last dose should be given around 4 PM (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21312290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21312290'])">Ref</a></span>)).</p></div>
<div class="block use drugH1Div" id="F132653"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Drug-induced parkinsonism (IR and ER tablet only):</b> Treatment of drug-induced parkinsonism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease, dyskinesias (adjunctive therapy) or mild motor symptoms (monotherapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Extended release:</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule: Treatment of dyskinesias in patients with Parkinson disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; treatment of "off" episodes in patients with Parkinson disease receiving levodopa/carbidopa.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablet: Treatment of Parkinson disease.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Treatment of idiopathic Parkinson disease (paralysis agitans), postencephalitic parkinsonism, parkinsonism in association with cerebral arteriosclerosis, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication.</p></div>
<div class="block off-label drugH1Div" id="F25816118"><span class="drugH1">Use: Off-Label: Adult</span><p>Multiple sclerosis–related fatigue; Neuroleptic malignant syndrome, moderate to severe; Tardive dyskinesia</p></div>
<div class="block mst drugH1Div" id="F132723"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amantadine may be confused with amiodarone, raNITIdine, riMANTAdine </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Symmetrel may be confused with Synthroid</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298728"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT1, OCT2</p></div>
<div class="block dri drugH1Div" id="F132644"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of Amantadine. Alcohol may also cause dose-dumping for at least one extended-release amantadine product.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alkalinizing Agents: May increase the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Injection): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride (Oral). Amisulpride (Oral) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: Amantadine may enhance the anticholinergic effect of Anticholinergic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (First Generation [Typical]): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible. If antipsychotic use is necessary, consider using atypical antipsychotics such as clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Specifically, the risk of chorea may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May increase the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Systemic): Amantadine may enhance the anticholinergic effect of Glycopyrrolate (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid administration of live influenza virus vaccine (LAIV) within 2 weeks before or 48 hours after administration of antiviral agents. Consider avoiding LAIV if peramivir was given within the last 5 days or baloxavir was given within the last 17 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Kava Kava may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Memantine: NMDA Receptor Antagonists may enhance the adverse/toxic effect of Memantine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propiverine: May enhance the adverse/toxic effect of Amantadine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: Amantadine may enhance the anticholinergic effect of QuiNIDine. QuiNIDine may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus or delirium may be increased. Trimethoprim may increase the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urinary Acidifying Agents: May decrease the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F132660"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in animal reproduction studies, and teratogenic events have been observed in humans (case reports) (Seier 2017).</p>
<p style="text-indent:0em;margin-top:2em;">When treatment for Parkinson disease is needed, agents other than amantadine are recommended in pregnant women (Seier 2017).</p></div>
<div class="block brc drugH1Div" id="F11313487"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Amantadine is present in breast milk. Amantadine may alter breast milk production or excretion. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F132648"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Renal function (baseline and as clinically indicated), mental status (especially at initiation and after dose increases) including psychosis, hallucinations, depression and suicidality, dizziness, blood pressure, and orthostasis (as clinically indicated).</p>
<p style="text-indent:-2em;margin-left:2em;">Neuroleptic malignant syndrome: Electrolytes, PT/INR, aPTT, creatine kinase level, urine output, vital signs (including temperature) (Strawn 2007).</p></div>
<div class="block pha drugH1Div" id="F132638"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Antiviral:</p>
<p style="text-indent:-2em;margin-left:4em;">Amantadine is no longer recommended as an antiviral (CDC 2020; IDSA [Uyeki 2019]). The mechanism of amantadine’s antiviral activity has not been fully elucidated. It appears to primarily prevent the release of infectious viral nucleic acid into the host cell by interfering with the transmembrane domain of the viral M2 protein. Amantadine is also known to prevent viral assembly during replication. Amantadine inhibits the replication of influenza A virus isolates from each of the subtypes (ie, H1N1, H2N2, and H3N2), but has very little or no activity against influenza B virus isolates.</p>
<p style="text-indent:-2em;margin-left:2em;">Parkinson disease:</p>
<p style="text-indent:-2em;margin-left:4em;">The exact mechanism of amantadine in the treatment of Parkinson disease and drug-induced extrapyramidal symptoms is not known. Data from early animal studies suggest that amantadine may have direct and indirect effects on dopamine neurons; however, recent studies have demonstrated that amantadine is a weak, noncompetitive NMDA receptor antagonist. Although amantadine has not been shown to possess direct anticholinergic activity, clinically, it exhibits anticholinergic-like side effects (dry mouth, urinary retention, and constipation).</p></div>
<div class="block phk drugH1Div" id="F132655"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Antidyskinetic: Within 48 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Normal: 3 to 8 L/kg; Renal failure: 5.1 ± 0.2 L/kg (Aoki 1988)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Normal renal function: ~67%; Hemodialysis: ~59% (Aoki 1988)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not appreciable; small amounts of an acetyl metabolite identified</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Immediate release: 86% to 94% (Aoki 1988)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Normal renal function: 16 ± 6 hours (9 to 31 hours); Healthy, older (≥60 years) males: 29 hours (range: 20 to 41 hours) (Aoki 1988); End-stage renal disease: 8 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Extended-release capsule: 12 hours (mean; range: 6 to 20 hours); extended-release tablet: 7.5 hours (median; range: 5.5 to 12 hours); immediate release: 2 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80% to 90% unchanged) by glomerular filtration and tubular secretion</p></div>
<div class="block phksp drugH1Div" id="F51220175"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination half-life is increased 2- to 3-fold or greater when CrCl is less than 40 mL/minute/1.73 m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Clearance is reduced</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F132661"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Amantadine | Symmetrel</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Actison | Ampakine | Virosol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Amantadinsulfate fresenius kabi | Hofcomant | Pk merz | Virucid</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Symmetrel</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Amantril | Fluzit | Influ</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Amantan | Mantadix</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Pk merz | Viregyt k</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Mantidan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Pk merz | Symmetrel</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Prayanol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Amantadine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Amantadina | Amantix | Zintergia</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Pk merz | Viregyt k</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">A.m.t. | Aman | Amanta | Amanta hcl | Amanta sulfat | Amantadin | Amantadin 1 A Pharma | Amantadin-CT | Amantadin-neuraxpharm | Amantadin-Sulfat Sandoz | Amantadine | Amantagamma | Amixx | Infex | Pk merz | Tregor</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Amantadina | Pk merz</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Pk merz</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Amantadin ratiopharm | Midantan | Pk merz</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adamine | Amantine | Infex | Pk merz | Viraflu</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Amantadina cidan | Amantadine level | Amantadine Llorente</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Atarin | Paramantin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mantadix</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Amantadine | Lysovir | Mantadine | Symmetrel</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Symmetrel</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Amantadine | Enzil | Pk merz | Pms amantadine hydrochloride | Symmetrel | Viracon</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Pk merz</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Pk merz | Viregyt k</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Symmetrel</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Amantadine | Amantadine hydrochloride renata | Symmetrel</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">A-Parkin | Paritrel | Pk merz | Symmetrel</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Amantex | Amantrel | Comantrel | Comantrel t | Ensorex | Parkitidin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mantadan</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Pk merz</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amantadine Hcl Nichiiko | Amazolon | Atenegine | Boidan | Lusyton | Rotifamin | Shikitan | Symmetrel | Topharmin amel | Topharmin mita</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amanta | Parkintrel | Pk merz | Simetan | Tantron</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Pk merz | Symmetrel</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Amantadin | Midantan | Pk merz | Viregyt k</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Amantan | Pk merz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Amantadin ratiopharm | Midantan | Neomidantan | Pk merz | Viregyt k</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amantadina | Kinestrel | Pk merz</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Pk merz | Symmetrel</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Symmetrel</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Amantadin | Amantadin neuraxpharm | Amantadin stada | Dinetrel | Symmetrel</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Symmetrel</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Symmetrel</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Amatamerz | Pk merz</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Amantadin | Amantadin stada | Amantix | Viregyt k</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Amantadine HCL | Gocovri | Symmetrel</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Parkadina | Pk merz</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Amantadina clorhidrato eurofarma | Amantadina promepar</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Viregyt k</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Amantadine | Midantan | Neomidantan | Pk merz</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Pdp amantadine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dinetrel | Symmetrel</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Symmetrel</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Symmetrel</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Pk merz | Viregyt k</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Amantadine neuraxpharm | Amantex | Mantadix</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Amantadin | Pk merz</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Amadine | Amanda | Amandin | Amandine | Amantadin | Amantadine | Amantec | Amanxin | Amtadine | Anasin | Anrigin | Antadine | Atadin | Decold | Dopadine | Enzil | Influ | Manta | Pk merz | Protexin | Simon | Sumon | Topharmin | Unitadin | Viracon</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Amantin | Midantan | Pk merz</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Amandine | Efantadine | Pk merz</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Symadin | Symmetrel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Amantadine hydrochloride capsules [prescribing information]. New Castle, DE: Marlex Pharmaceuticals Inc; October 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/Marlex.1/pubmed" id="Marlex.1" target="_blank">Marlex.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ChartwellRX.1">
<a name="ChartwellRX.1"></a>Amantadine hydrochloride oral solution [prescribing information]. Congers, NY: Chartwell RX; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Marlex.2">
<a name="Marlex.2"></a>Amantadine hydrochloride tablets [prescribing information]. New Castle, DE: Marlex Pharmaceuticals Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32900875">
<a name="32900875"></a>American Academy of Pediatrics (AAP) Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2020-2021. <i>Pediatrics</i>. 2020;146(4):e2020024588. doi:10.1542/peds.2020-024588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/32900875/pubmed" id="32900875" target="_blank">32900875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10950469">
<a name="10950469"></a>Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. <i>J Clin Psychopharmacol</i>. 1997;17(2):88-91. doi:10.1097/00004714-199704000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/10950469/pubmed" id="10950469" target="_blank">10950469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3280212">
<a name="3280212"></a>Aoki FY, Sitar DS. Clinical Pharmacokinetics of Amantadine Hydrochloride. <i>Clin Pharmacokinet</i>. 1988;14(1):35-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/3280212/pubmed" id="3280212" target="_blank">3280212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24963407">
<a name="24963407"></a>Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. <i>Mult Scler Int</i>. 2014;2014:798285. doi:10.1155/2014/798285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/24963407/pubmed" id="24963407" target="_blank">24963407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31700703">
<a name="31700703"></a>Barone P, Antonini A, Stanzione P, Annoni K, Asgharnejad M, Bonuccelli U. Risk factors for impulse control disorders and related behaviors in Parkinson's disease: secondary analyses of the ICARUS study. <i>J Drug Assess</i>. 2019;8(1):159-166. doi:10.1080/21556660.2019.1675670<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/31700703/pubmed" id="31700703" target="_blank">31700703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21995348">
<a name="21995348"></a>Barrera F, Browning JC. Likely amantadine-induced livedo reticularis in a child. <i>Pediatr Dermatol</i>. 2012;29(3):329-330. doi:10.1111/j.1525-1470.2011.01437.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21995348/pubmed" id="21995348" target="_blank">21995348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21391319">
<a name="21391319"></a>Beal E. Parkinson disease: amantadine administration is associated with impulse control disorders in PD. <i>Nat Rev Neurol</i>. 2011;7(2):62. doi:10.1038/nrneurol.2010.206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21391319/pubmed" id="21391319" target="_blank">21391319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16170253">
<a name="16170253"></a>Beers SR, Skold A, Dixon CE, et al. Neurobehavioral Effects of Amantadine After Pediatric Traumatic Brain Injury: A Preliminary Report. <i>J Head Trauma Rehabil</i>. 2005;20(5):450-463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/16170253/pubmed" id="16170253" target="_blank">16170253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16942542">
<a name="16942542"></a>Benbir G, Ozekmekçi S, Cinar M, Beskardes F, Apaydin H, Erginöz E. Features associated with the development of hallucinations in Parkinson's disease. <i>Acta Neurol Scand</i>. 2006;114(4):239-243. doi:10.1111/j.1600-0404.2006.00644.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/16942542/pubmed" id="16942542" target="_blank">16942542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15062519">
<a name="15062519"></a>Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. <i>Neurol Clin</i>. 2004;22(2):389-411. doi:10.1016/j.ncl.2003.12.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/15062519/pubmed" id="15062519" target="_blank">15062519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23897874">
<a name="23897874"></a>Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA; American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2013;81(5):463-469. doi:10.1212/WNL.0b013e31829d86b6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/23897874/pubmed" id="23897874" target="_blank">23897874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22732295">
<a name="22732295"></a>Bienvenu OJ, Neufeld KJ, Needham DM. Treatment of four psychiatric emergencies in the intensive care unit. <i>Crit Care Med</i>. 2012;40(9):2662-2670. doi:10.1097/CCM.0b013e31825ae0f8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22732295/pubmed" id="22732295" target="_blank">22732295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34370054">
<a name="34370054"></a>Cao L, Xu T, Zhao G, Lv D, Lu J, Zhao G. Risk factors of impulsive-compulsive behaviors in PD patients: a meta-analysis. <i>J Neurol</i>. 2022;269(3):1298-1315. doi:10.1007/s00415-021-10724-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/34370054/pubmed" id="34370054" target="_blank">34370054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Updated November 30, 2020. Accessed December 31, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Last reviewed May 6, 2021. Accessed August 3, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24971012">
<a name="24971012"></a>Cera N, Bifolchetti S, Martinotti G, et al. Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders. <i>Neuropsychiatr Dis Treat</i>. 2014;10:1093-1101. doi:10.2147/NDT.S54423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/24971012/pubmed" id="24971012" target="_blank">24971012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21541715">
<a name="21541715"></a>Cilia R, van Eimeren T. Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. <i>Brain Struct Funct</i>. 2011;216(4):289-299. doi:10.1007/s00429-011-0314-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21541715/pubmed" id="21541715" target="_blank">21541715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26338517">
<a name="26338517"></a>Criado PR, Alavi A, Valente NY, Sotto MN. Amantadine-induced livedo racemosa. <i>Int J Low Extrem Wounds</i>. 2016;15(1):78-81. doi:10.1177/1534734615603566<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/26338517/pubmed" id="26338517" target="_blank">26338517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31456212">
<a name="31456212"></a>Cutsforth-Gregory JK, Low PA. Neurogenic orthostatic hypotension in Parkinson Disease: a primer. <i>Neurol Ther</i>. 2019;8(2):307-324. doi:10.1007/s40120-019-00152-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/31456212/pubmed" id="31456212" target="_blank">31456212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5066">
<a name="5066"></a>DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE. A controlled trial of amantadine in drug-induced extrapyramidal disorders. <i>Arch Gen Psychiatry</i>. 1976;33(5):599-602. doi:10.1001/archpsyc.1976.01770050055008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/5066/pubmed" id="5066" target="_blank">5066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17979585">
<a name="17979585"></a>Donfrancesco R, Calderoni D, Vitiello B. Open-Label Amantadine in Children With Attention-Deficit/Hyperactivity Disorder. <i>J Child Adolesc Psychopharmacol</i>. 2007;17(5):657-664.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/17979585/pubmed" id="17979585" target="_blank">17979585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34190209">
<a name="34190209"></a>Dos Santos DT, Imthon AK, Strelow MZ, Pille A, Schumacher-Schuh AF. Parkinsonism-hyperpyrexia syndrome after amantadine withdrawal: case report and review of the literature. <i>Neurologist</i>. 2021;26(4):149-152. doi:10.1097/NRL.0000000000000330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/34190209/pubmed" id="34190209" target="_blank">34190209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19515253">
<a name="19515253"></a>Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study. <i>BMC Neurol</i>. 2009;9:23. doi:10.1186/1471-2377-9-23<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/19515253/pubmed" id="19515253" target="_blank">19515253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10734005">
<a name="10734005"></a>Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. <i>Brain</i>. 2000;123 ( Pt 4):733-745. doi:10.1093/brain/123.4.733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/10734005/pubmed" id="10734005" target="_blank">10734005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28492457">
<a name="28492457"></a>Fryml LD, Williams KR, Pelic CG, et al. The role of amantadine withdrawal in 3 cases of treatment-refractory altered mental status. <i>J Psychiatr Pract</i>. 2017;23(3):191-199. doi:10.1097/PRA.0000000000000237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/28492457/pubmed" id="28492457" target="_blank">28492457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22375973">
<a name="22375973"></a>Giacino JT, Whyte J, Bagiella E, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. <i>N Engl J Med</i>. 2012;366(9):819-8126. doi:10.1056/NEJMoa1102609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22375973/pubmed" id="22375973" target="_blank">22375973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gocovri.1">
<a name="Gocovri.1"></a>Gocovri (amantadine hydrochloride) [prescribing information]. Emeryville, CA: Adamas Pharma LLC; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19299325">
<a name="19299325"></a>Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. <i>Ann Pharmacother</i>. 2009;43(4):785-791. doi:10.1345/aph.1L371<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/19299325/pubmed" id="19299325" target="_blank">19299325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28861870">
<a name="28861870"></a>Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, et al. Dopamine agonists and impulse control disorders: a complex association. <i>Drug Saf</i>. 2018;41(1):19-75. doi:10.1007/s40264-017-0590-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/28861870/pubmed" id="28861870" target="_blank">28861870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30581218">
<a name="30581218"></a>Grover S, Sathpathy A, Reddy SC, Mehta S, Sharma N. Parkinsonism-hyperpyrexia syndrome: a case report and review of literature. <i>Indian J Psychiatry</i>. 2018;60(4):499-503. doi:10.4103/psychiatry.IndianJPsychiatry_113_18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/30581218/pubmed" id="30581218" target="_blank">30581218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30372725">
<a name="30372725"></a>Helmandollar KJ, Hoverson KR, Meyerle JH. Amantadine-induced livedo reticularis in a child treated off label for neurobehavioral disorders. <i>Cutis</i>. 2018;102(3):E8-E9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/30372725/pubmed" id="30372725" target="_blank">30372725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7212501">
<a name="7212501"></a>Horadam VW, Sharp JG, Smilack JD, et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. <i>Ann Intern Med</i>. 1981;94(4, pt 1):454-458. doi:10.7326/0003-4819-94-4-454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/7212501/pubmed" id="7212501" target="_blank">7212501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23390434">
<a name="23390434"></a>Hosenbocus S, Chahal R. Amantadine: a review of use in child and adolescent psychiatry. <i>J Can Acad Child Adolesc Psychiatry</i>. 2013;22(1):55-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/23390434/pubmed" id="23390434" target="_blank">23390434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11421428">
<a name="11421428"></a>Ito T, Shibata K, Watanabe A, Akabane J. Neuroleptic malignant syndrome following withdrawal of amantadine in a patient with influenza A encephalopathy. <i>Eur J Pediatr</i>. 2001;160(6):401. doi:10.1007/s004310100743<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/11421428/pubmed" id="11421428" target="_blank">11421428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22784693">
<a name="22784693"></a>Joutsa J, Martikainen K, Vahlberg T, Kaasinen V. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. <i>Parkinsonism Relat Disord</i>. 2012;18(10):1079-1083. doi:10.1016/j.parkreldis.2012.06.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22784693/pubmed" id="22784693" target="_blank">22784693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11392343">
<a name="11392343"></a>King BH, Wright DM, Handen BL, et al. Double-Blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of Children With Autistic Disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2001a;40(6):658-665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/11392343/pubmed" id="11392343" target="_blank">11392343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11392342">
<a name="11392342"></a>King BH, Wright DM, Snape M, Dourish CT. Case series: amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities. J Am Acad Child Adolesc Psychiatry. 2001b;40(6):654-657. doi:10.1097/00004583-200106000-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/11392342/pubmed" id="11392342" target="_blank">11392342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34324057">
<a name="34324057"></a>Koschel J, Ray Chaudhuri K, Tönges L, Thiel M, Raeder V, Jost WH. Implications of dopaminergic medication withdrawal in Parkinson's disease. <i>J Neural Transm (Vienna)</i>. 2022;129(9):1169-1178. doi:10.1007/s00702-021-02389-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/34324057/pubmed" id="34324057" target="_blank">34324057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24321164">
<a name="24321164"></a>Ledinek AH, Sajko MC, Rot U. Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis—result of a pilot randomized, blind study. <i>Clin Neurol Neurosurg</i>. 2013;115(suppl 1):S86-S89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/24321164/pubmed" id="24321164" target="_blank">24321164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21280095">
<a name="21280095"></a>Lee JY, Kim HJ, Jeon BS. Is pathological gambling in Parkinson's disease reduced by amantadine? <i>Ann Neurol</i>. 2011;69(1):213-214; author reply 214-5. doi:10.1002/ana.22289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21280095/pubmed" id="21280095" target="_blank">21280095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22674352">
<a name="22674352"></a>Lee AH, Weintraub D. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. <i>Mov Disord</i>. 2012;27(7):858-863. doi:10.1002/mds.25003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22674352/pubmed" id="22674352" target="_blank">22674352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Liang.1">
<a name="Liang.1"></a>Liang TW. Medical management of motor fluctuations and dyskinesia in Parkinson disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31733691">
<a name="31733691"></a>Lizarraga KJ, Fox SH, Strafella AP, Lang AE. Hallucinations, delusions and impulse control disorders in Parkinson Disease. <i>Clin Geriatr Med</i>. 2020;36(1):105-118. doi:10.1016/j.cger.2019.09.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/31733691/pubmed" id="31733691" target="_blank">31733691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31167116">
<a name="31167116"></a>Liu B, Luo W, Mo Y, Wei C, Tao R, Han M. Meta-analysis of related factors of impulse control disorders in patients with Parkinson's disease. <i>Neurosci Lett</i>. 2019;707:134313. doi:10.1016/j.neulet.2019.134313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/31167116/pubmed" id="31167116" target="_blank">31167116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28611642">
<a name="28611642"></a>Marxreiter F, Winkler J, Uhl M, Madžar D. A case report of severe delirium after amantadine withdrawal. <i>Case Rep Neurol</i>. 2017;9(1):44-48. doi:10.1159/000460814<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/28611642/pubmed" id="28611642" target="_blank">28611642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19404190">
<a name="19404190"></a>McMahon MA, Vargus-Adams JN, Michaud LJ, et al. Effects of Amantadine in Children With Impaired Consciousness Caused by Acquired Brain Injury: A Pilot Study. <i>Am J Phys Med Rehabil</i>. 2009;88(7):525-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/19404190/pubmed" id="19404190" target="_blank">19404190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15480845">
<a name="15480845"></a>Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. <i>J Neural Transm (Vienna)</i>. 2004;111(10-11):1447-1453. doi:10.1007/s00702-004-0209-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/15480845/pubmed" id="15480845" target="_blank">15480845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21312290">
<a name="21312290"></a>Mohammadi MR, Kazemi MR, Zia E, et al. Amantadine Versus Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Trial. <i>Hum Psychopharmacol</i>. 2010;25(7-8):560-565.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21312290/pubmed" id="21312290" target="_blank">21312290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33614044">
<a name="33614044"></a>Murray JP, Kerins A. Amantadine withdrawal syndrome masquerading as COVID-19 encephalopathy: a case report and review of the literature. <i>Oxf Med Case Reports</i>. 2021;2021(2):omaa133. doi:10.1093/omcr/omaa133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/33614044/pubmed" id="33614044" target="_blank">33614044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18712508">
<a name="18712508"></a>Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. <i>Neurocrit Care</i>. 2009;10(1):136-140. doi:10.1007/s12028-008-9125-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/18712508/pubmed" id="18712508" target="_blank">18712508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775657">
<a name="30775657"></a>Ngo V, Guerrero A, Lanum D, et al. Emergent treatment of neuroleptic malignant syndrome induced by antipsychotic monotherapy using dantrolene. <i>Clin</i>
<i>Pract Cases Emerg Med</i>. 2019;3(1):16-23. doi:10.5811/cpcem.2018.11.39667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/30775657/pubmed" id="30775657" target="_blank">30775657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33242419">
<a name="33242419"></a>Nourbakhsh B, Revirajan N, Morris B, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. <i>Lancet Neurol</i>. 2021;20(1):38-48. doi:10.1016/S1474-4422(20)30354-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/33242419/pubmed" id="33242419" target="_blank">33242419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Odan-Amantadine.1">
<a name="Odan-Amantadine.1"></a>Odan-Amantadine syrup (amantadine, USP) [product monograph]. Pointe-Claire, Quebec, Canada: Odan Laboratories Ltd; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28833562">
<a name="28833562"></a>Oertel W, Eggert K, Pahwa R, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). <i>Mov Disord</i>. 2017;32(12):1701-1709. doi:10.1002/mds.27131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/28833562/pubmed" id="28833562" target="_blank">28833562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Olek.1">
<a name="Olek.1"></a>Olek MJ, Narayan RN, Frohman EM, Frohman TC. Symptom management of multiple sclerosis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmolex.1">
<a name="Osmolex.1"></a>Osmolex ER (amantadine) [prescribing information]. Emeryville, CA: Adamas Pharma LLC; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21121175">
<a name="21121175"></a>Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. <i>Clin Neuropharmacol</i>. 2010;33(6):271-275. doi:10.1097/wnf.0b013e3181ffde32<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21121175/pubmed" id="21121175" target="_blank">21121175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PDP.1">
<a name="PDP.1"></a>PDP-Amantadine hydrochloride capsules and syrup [product monograph]. Montreal, Quebec, Canada: Pendopharm; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22336566">
<a name="22336566"></a>Perez-Lloret S, Rey MV, Fabre N, et al. Factors related to orthostatic hypotension in Parkinson's disease. <i>Parkinsonism Relat Disord</i>. 2012;18(5):501-505. doi:10.1016/j.parkreldis.2012.01.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22336566/pubmed" id="22336566" target="_blank">22336566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23205015">
<a name="23205015"></a>Pettorruso M, Martinotti G, Di Nicola M, et al. Amantadine in the treatment of pathological gambling: a case report. <i>Front Psychiatry</i>. 2012;3:102. doi:10.3389/fpsyt.2012.00102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/23205015/pubmed" id="23205015" target="_blank">23205015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27423483">
<a name="27423483"></a>Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2016;50(11):973-981. doi:10.1177/1060028016657553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/27423483/pubmed" id="27423483" target="_blank">27423483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17438239">
<a name="17438239"></a>Pohl D, Waubant E, Banwell B, et al. Treatment of Pediatric Multiple Sclerosis and Variants. <i>Neurology</i>. 2007;68(16)(suppl 2):54-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/17438239/pubmed" id="17438239" target="_blank">17438239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-123540">
<a name="123540"></a>Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). <i>J Am Geriatr Soc</i>. 1975;23(5):212-215. doi:10.1111/j.1532-5415.1975.tb00187.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/123540/pubmed" id="123540" target="_blank">123540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26560223">
<a name="26560223"></a>Quaresma MV, Gomes AC, Serruya A, Vendramini DL, Braga L, Buçard AM. Amantadine-induced livedo reticularis--case report. <i>An Bras Dermatol</i>. 2015;90(5):745-747. doi:10.1590/abd1806-4841.20153394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/26560223/pubmed" id="26560223" target="_blank">26560223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22356509">
<a name="22356509"></a>Rana AQ, Masroor MS. Patient perception of Levido reticularis due to amantadine. <i>Int J Neurosci</i>. 2012;122(7):363-366. doi:10.3109/00207454.2012.668727<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22356509/pubmed" id="22356509" target="_blank">22356509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30791698">
<a name="30791698"></a>Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. <i>Can J Psychiatry</i>. 2019;64(6):388-399. doi:10.1177/0706743719828968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/30791698/pubmed" id="30791698" target="_blank">30791698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21217832">
<a name="21217832"></a>Sawada H, Oeda T, Kuno S, et al; Amantadine Study Group. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. <i>PLoS One</i>. 2010;5(12):e15298. doi:10.1371/journal.pone.0015298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21217832/pubmed" id="21217832" target="_blank">21217832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28506531">
<a name="28506531"></a>Seier M, Hiller A. Parkinson's disease and pregnancy: An updated review. <i>Parkinsonism Relat Disord</i>. 2017;40:11-17. doi:10.1016/j.parkreldis.2017.05.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/28506531/pubmed" id="28506531" target="_blank">28506531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30653247">
<a name="30653247"></a>Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. <i>Mov Disord</i>. 2019;34(2):180-198. doi:10.1002/mds.27602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/30653247/pubmed" id="30653247" target="_blank">30653247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25745311">
<a name="25745311"></a>Sharma A, Goyal V, Behari M, Srivastva A, Shukla G, Vibha D. Impulse control disorders and related behaviours (ICD-RBs) in Parkinson's disease patients: assessment using "Questionnaire for impulsive-compulsive disorders in Parkinson's disease" (QUIP). <i>Ann Indian Acad Neurol</i>. 2015;18(1):49-59. doi:10.4103/0972-2327.144311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/25745311/pubmed" id="25745311" target="_blank">25745311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22979982">
<a name="22979982"></a>Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. <i>Neurol Res</i>. 2012;34(9):854-858.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22979982/pubmed" id="22979982" target="_blank">22979982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5467552">
<a name="5467552"></a>Shealy CN, Weeth JB, Mercier D. Livedo reticularis in patients with parkinsonism receiving amantadine. <i>JAMA</i>. 1970;212(9):1522-1523.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/5467552/pubmed" id="5467552" target="_blank">5467552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1771145">
<a name="1771145"></a>Somani SK, Degelau J, Cooper SL, Guay DR, Ehresman D, Zaske D. Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents. <i>Pharmacotherapy</i>. 1991;11(6):460-466.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/1771145/pubmed" id="1771145" target="_blank">1771145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spindler.1">
<a name="Spindler.1"></a>Spindler M. Initial pharmacologic treatment of Parkinson disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2061537">
<a name="2061537"></a>Stange KC, Little DW, Blatnik B. Adverse reactions to amantadine prophylaxis of influenza in a retirement home. <i>J Am Geriatr Soc</i>. 1991;39(7):700-705. doi:10.1111/j.1532-5415.1991.tb03625.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/2061537/pubmed" id="2061537" target="_blank">2061537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17541044">
<a name="17541044"></a>Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. <i>Am J Psychiatry</i>. 2007;164(6):870-876. doi: 10.1176/ajp.2007.164.6.870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/17541044/pubmed" id="17541044" target="_blank">17541044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.1">
<a name="Stroup.1"></a>Stroup T, Marder S. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32306929">
<a name="32306929"></a>Szota AM, Radajewska I, Grudzka P, Araszkiewicz A. Lamotrigine, quetiapine and aripiprazole-induced neuroleptic malignant syndrome in a patient with renal failure caused by lithium: a case report. <i>BMC Psychiatry</i>. 2020;20(1):179. doi:10.1186/s12888-020-02597-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/32306929/pubmed" id="32306929" target="_blank">32306929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12735913">
<a name="12735913"></a>Takubo H, Harada T, Hashimoto T, et al. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. <i>Parkinsonism Relat Disord</i>. 2003;9 (Suppl 1):S31-41. doi:10.1016/s1353-8020(02)00122-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/12735913/pubmed" id="12735913" target="_blank">12735913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31929122">
<a name="31929122"></a>Tanner CM, Pahwa R, Hauser RA, et al. EASE LID 2: a 2-year open-label trial of Gocovri (Amantadine extended release for dyskinesia in Parkinson's Disease. <i>J Parkinsons Dis</i>. 2020;10(2):543-558. doi:10.3233/JPD-191841<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/31929122/pubmed" id="31929122" target="_blank">31929122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20687121">
<a name="20687121"></a>Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine.<i> Ann Neurol</i>. 2010;68(3):400-404. doi:10.1002/ana.22029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/20687121/pubmed" id="20687121" target="_blank">20687121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30566567">
<a name="30566567"></a>Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. <i>Clin Infect Dis</i>. 2019;68(6):e1-e47. doi:10.1093/cid/ciy866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/30566567/pubmed" id="30566567" target="_blank">30566567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23611687">
<a name="23611687"></a>Valença GT, Glass PG, Negreiros NN, et al. Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease. <i>Parkinsonism Relat Disord</i>. 2013;19(7):698-700. doi:10.1016/j.parkreldis.2013.03.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/23611687/pubmed" id="23611687" target="_blank">23611687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30858642">
<a name="30858642"></a>van Rensburg R, Decloedt EH. An approach to the pharmacotherapy of neuroleptic malignant syndrome. <i>Psychopharmacol</i>
<i>Bull</i>. 2019;49(1):84-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/30858642/pubmed" id="30858642" target="_blank">30858642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20129511">
<a name="20129511"></a>Vargus-Adams JN, McMahon MA, Michaud LJ, et al. Pharmacokinetics of Amantadine in Children With Impaired Consciousness Due to Acquired Brain Injury: Preliminary Findings Using a Sparse-Sampling Technique. <i>PMR</i>. 2010;2(1):37-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/20129511/pubmed" id="20129511" target="_blank">20129511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5580722">
<a name="5580722"></a>Vollum DI, Parkes JD, Doyle D. Livedo reticularis during amantadine treatment. <i>Br Med J</i>. 1971;2(5762):627-628. doi:10.1136/bmj.2.5762.627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/5580722/pubmed" id="5580722" target="_blank">5580722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21954056">
<a name="21954056"></a>Walsh RA, Lang AE. Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. <i>Mov Disord</i>. 2012;27(2):326. doi:10.1002/mds.23964<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21954056/pubmed" id="21954056" target="_blank">21954056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20457959">
<a name="20457959"></a>Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. <i>Arch Neurol</i>. 2010a;67(5):589-595. doi:10.1001/archneurol.2010.65<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/20457959/pubmed" id="20457959" target="_blank">20457959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21154480">
<a name="21154480"></a>Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Ann Neurol</i>. 2010b;68(6):963-968. doi:10.1002/ana.22164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21154480/pubmed" id="21154480" target="_blank">21154480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17729042">
<a name="17729042"></a>Williams SE. Amantadine Treatment Following Traumatic Brain Injury in Children. <i>Brain Inj</i>. 2007;21(9):885-889.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/17729042/pubmed" id="17729042" target="_blank">17729042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7035042">
<a name="7035042"></a>Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. <i>Clin Nephrol</i>. 1982;17(1):19-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/7035042/pubmed" id="7035042" target="_blank">7035042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22165049">
<a name="22165049"></a>Xu LY, Liu A, Kerr HA. Livedo reticularis from amantadine. <i>Skinmed</i>. 2011;9(5):320-321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22165049/pubmed" id="22165049" target="_blank">22165049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27103808">
<a name="27103808"></a>Xu WJ, Wei N, Xu Y, Hu SH. Does amantadine induce acute psychosis? A case report and literature review. <i>Neuropsychiatr Dis Treat</i>. 2016;12:781-783. doi:10.2147/NDT.S101569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/27103808/pubmed" id="27103808" target="_blank">27103808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9143857">
<a name="9143857"></a>Young BK, Camicioli R, Ganzini L. Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. <i>Drugs Aging</i>. 1997;10(5):367-383. doi:10.2165/00002512-199710050-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/9143857/pubmed" id="9143857" target="_blank">9143857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6470196">
<a name="6470196"></a>Zubenko GS, Barreira P, Lipinski JF Jr. Development of Tolerance to the Therapeutic Effect of Amantadine on Akathisia. <i>J Clin Psychopharmacol</i>. 1984;4(4):218-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/6470196/pubmed" id="6470196" target="_blank">6470196</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8508 Version 544.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
